Singapore Launches State of the Art Cell Therapy Facility: Revolutionizing Cancer Treatment

PRESS RELEASE

Revolutionizing Cell Gene Therapy Capabilities in Singapore with New National Facility

The Advanced Cell Therapy and Research Institute, Singapore ACTRIS has unveiled a state-of-the-art 2,000 sqm cell therapy facility designed to address the escalating demand for cell and gene therapy treatments across Singapore. This comprehensive national center is equipped with thirteen Good Manufacturing Practice-compliant GMP clean suites, four translational laboratories, and one quality control laboratory-the largest of its kind in Singapore, empowering hospitals, academic institutions, and biotech startups.

The facility boasts advanced infrastructure that supports critical cell therapy processes including cell selection, genetic modification, closed-system manufacturing, and product storage. By harnessing sophisticated r-handling systems, ACTRIS is capable of concurrently producing multiple cell therapy products, thereby expediting patient access to these cutting-edge treatments.

Context on Cell Gene Therapy

Singapore anticipates that one in four citizens aged 75 will receive a cancer diagnosis by their lifetime. Cell and gene therapies CGTs are emerging as transformative options for certn forms of blood cancer. CGT innovations have ushered in the possibility of treating cancer through living drugs that utilize patients' immune cells to target specific cancerous cells.

Specific Process in Singapore

In Singapore, a CAR-T therapy exemplifies this innovative approach. This treatment involves collecting a patient's immune cells at hospitals and transporting them to a GMP facility like ACTRIS for processing. includes increasing the potency of these T-cells through genetic modification, expanding their numbers via cell expansion, followed by rigorous quality testing to ensure optimal product safety and efficacy before re-administration.

Facility Impact Collaborative Efforts

The new ACTRIS facility is poised to significantly enhance capacity in CGT development and manufacturing for local hospitals and research institutions. This strategic investment will catalyze groundbreaking work that advances cancer treatment, regenerative medicine, while fostering more public-private partnerships and regulatory approvals for cell therapy products.

Supporting Collaborations

Actively engaging with academic partners, hospital clusters, biotechnology and pharmaceutical industry, ACTRIS facilitate a thriving ecosystem of innovation. This new facility will accelerate the adoption of cell therapies in Singapore's healthcare system, potentially revolutionizing patient care delivery and accessibility to life-saving treatments.

Official Launch Future Projections

The launch was marked by Minister for Health Mr Ong Ye Kung at the inaugural Singapore Cell and Gene Therapy Conference on August 4th. Additionally, ACTRIS announced a joint funding initiative with the National Health Innovation Centre Singapore NHIC to expedite cell therapy implementation in hospitals, enhancing healthcare delivery and patient outcomes.

Contacts

For media inquiries:

• Charlene Tan, Assistant Manager, Corporate Communications

  • [email protected]

• Lynette Lan, Senior Manager, Corporate Communications

  • [email protected]

About CRIS

Consortium for Clinical Research and Innovation, Singapore CRIS is dedicated to advancing healthcare through innovative research initiatives.

of Press Release

This press release provides an enhanced version in English format that focuses on the key aspects of ACTRIS's new facility and its impact on cell gene therapy capabilities in Singapore.
This article is reproduced from: https://cris.sg/news-and-events/media-releases/230804-actris-cell-therapy-facility/

Please indicate when reprinting from: https://www.051m.com/Biotechnology_companies/ACTRIS-cell_therapy_facility_Singapore.html